This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Zumutor Biologics Inc.
Monte Rosa Therapeutics, Inc
OncoNano Medicine, Inc.
Incyte Corporation
Immunitas Therapeutics
Nurix Therapeutics, Inc.
Seagen Inc.
Celldex Therapeutics
Eastern Cooperative Oncology Group
Humanitas Hospital, Italy
University Hospital Southampton NHS Foundation Trust
Incyte Corporation
Jonsson Comprehensive Cancer Center
University of Wisconsin, Madison
Vanderbilt-Ingram Cancer Center
Rennes University Hospital
City of Hope Medical Center
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Vanderbilt-Ingram Cancer Center
Wake Forest University Health Sciences
European Organisation for Research and Treatment of Cancer - EORTC
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
University of Louisville
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
Rutgers, The State University of New Jersey
Barbara Ann Karmanos Cancer Institute
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Washington University School of Medicine
National Cancer Institute (NCI)
Indiana University
University of Minnesota
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
Roswell Park Cancer Institute